Bengaluru, Karnataka, India, May 2025 — Sethu Madhavan Sankaran has been appointed as the Chief Operating Officer at PlasmaGen BioSciences (P) Ltd, a pioneering Indian biopharmaceutical company specializing in plasma-derived therapies. With over 27 years of multifaceted leadership experience across the pharmaceutical and chemical sectors, Sethu brings a wealth of expertise to his new role, where he will spearhead manufacturing scale-up, enhance operational efficiency, and strengthen regulatory compliance and quality systems.
Before joining PlasmaGen, Sethu was Senior Vice President – Operations and Capital Investments at Granules India Limited, where he led critical infrastructure and efficiency initiatives. Prior to that, he spent over a decade at Biocon Biologics, where he served as Global Head – Insulin Operations, managing manufacturing operations in India and Malaysia, and previously as Manufacturing Head – Insulin Analogs and Biosimilars, overseeing Biocon’s Bangalore facility with a focus on infrastructure revamp, lean implementation, and operational excellence.
Earlier in his career, Sethu held senior leadership roles at Teva Pharmaceuticals, serving as Director – Manufacturing at Teva API and as Sr. Manager/Associate Director at Teva Pharmaceuticals, where he managed pilot plant operations and scale-up activities. His foundational years included impactful roles at Ranbaxy Research, Dr. Reddy’s Laboratories, and Herdillia Chemicals, where he built strong capabilities in technology transfer, regulatory compliance, and process development.
A specialist in sterile injectables, small molecules, and biologics, Sethu is well-versed in Lean, Six Sigma, and international compliance frameworks. His appointment marks a strategic milestone in PlasmaGen’s journey towards scaling its domestic manufacturing footprint and expanding into international markets.
About PlasmaGen BioSciences (P) Ltd
Founded in 2010 and headquartered in Bengaluru, PlasmaGen BioSciences is India’s first company dedicated exclusively to plasma protein therapeutics. Committed to improving patient access to life-saving plasma-derived products, PlasmaGen addresses key therapeutic areas including rare and genetic diseases such as hemophilia, thalassemia, and primary immunodeficiencies. With a state-of-the-art manufacturing facility nearing completion in Kolar, PlasmaGen aims to support India’s self-sufficiency in plasma protein availability while promoting awareness and responsible plasma management nationwide.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
